Affinage

TRIM11

E3 ubiquitin-protein ligase TRIM11 · UniProt Q96F44

Length
468 aa
Mass
52.8 kDa
Annotated
2026-04-28
69 papers in source corpus 28 papers cited in narrative 28 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TRIM11 is a RING-domain E3 ubiquitin ligase that functions as a central regulator of protein quality control and signal transduction through ubiquitin-dependent degradation, molecular chaperoning, and disaggregase activity. TRIM11 promotes K48-linked ubiquitination and proteasomal degradation of diverse substrates including Humanin, PAX6, ARC105, Axin1, PHLPP1, and PHOX2B, and additionally activates the proteasome by binding USP14 and displacing it from the 26S complex (PMID:12670303, PMID:18628401, PMID:29581427, PMID:31786079, PMID:31719797). Independent of ATP, TRIM11 acts as a molecular chaperone and disaggregase that prevents protein aggregation and dissolves preformed amyloid fibrils of α-synuclein and tau, coupling these activities with SUMO E3 ligase function to target aberrant proteins for degradation; AAV-mediated TRIM11 delivery ameliorates pathology in mouse models of Parkinson's disease and tauopathy (PMID:33264628, PMID:37499037, PMID:39286522). TRIM11 also restrains innate immune signaling by interacting with TBK1 to suppress IRF3 phosphorylation, directing AIM2 for p62-dependent selective autophagy to limit inflammasome activation, and engaging in a mutual regulatory axis with JAK1 in which JAK1-mediated phosphorylation stabilizes TRIM11 while TRIM11 promotes K63-linked ubiquitination of JAK1 to suppress JAK/STAT-driven PD-L1 expression (PMID:23675467, PMID:27498865, PMID:37804507, PMID:41203822).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 2003 Medium

    Establishing that TRIM11 is an E3 ligase directing substrates to the proteasome: the first demonstration that TRIM11 promotes ubiquitin-dependent proteasomal degradation of a binding partner (Humanin), requiring its RING domain.

    Evidence Yeast two-hybrid, co-expression assays, deletion mutagenesis, and proteasome inhibitor treatment in mammalian cells

    PMID:12670303

    Open questions at the time
    • No in vitro ubiquitination reconstitution
    • Physiological relevance of Humanin regulation unclear
    • E2 enzyme identity unknown
  2. 2006 Medium

    Extending TRIM11 substrate scope to a transcriptional cofactor: TRIM11 was shown to degrade ARC105 and thereby suppress TGF-β-dependent transcription, establishing TRIM11 as a regulator of signaling-pathway output.

    Evidence Co-immunoprecipitation, ubiquitination assay, proteasome inhibitor treatment, and TGF-β transcriptional reporter in mammalian cells

    PMID:16904669

    Open questions at the time
    • Single lab finding
    • Endogenous confirmation lacking
    • No in vivo validation
  3. 2008 High

    Linking TRIM11 to protein quality control and neurodevelopment: TRIM11 degrades PAX6 via its B30.2 domain and clears insoluble PAX6 aggregates in cortical progenitors; Pax6 itself transcriptionally activates Trim11, forming a feedback loop controlling neurogenesis.

    Evidence Co-IP, overexpression/knockdown in cortical progenitors, in vivo cortical electroporation, ChIP, and domain mutagenesis

    PMID:18628401

    Open questions at the time
    • Mechanism of insoluble protein clearance not biochemically dissected
    • Whether TRIM11 chaperone function versus ubiquitin ligase function drives aggregate clearance was unresolved
  4. 2012 Medium

    Demonstrating TRIM11 can rescue pathogenic protein aggregates: TRIM11 degrades polyalanine-expanded PHOX2B (causative for congenital central hypoventilation syndrome), restoring wild-type PHOX2B transcriptional function.

    Evidence Ubiquitination assays, proteasome inhibitor treatment, and transcriptional reporter assays in neuroblastoma cells

    PMID:22307522

    Open questions at the time
    • No in vivo disease model tested
    • Single lab
    • Whether TRIM11 distinguishes mutant from wild-type PHOX2B unclear
  5. 2013 High

    Revealing TRIM11 as a negative regulator of innate antiviral signaling: TRIM11 interacts with TBK1 via their respective coiled-coil domains, blocking IRF3 phosphorylation and dimerization and thereby suppressing IFN-β production.

    Evidence Reciprocal Co-IP with domain mapping, IFN-β promoter reporter, IRF3 phosphorylation assays, and viral infectivity assays

    PMID:23675467

    Open questions at the time
    • Whether TRIM11 ubiquitinates TBK1 or acts non-catalytically was not determined
    • In vivo immune phenotype not examined
  6. 2014 Medium

    Identifying a dual mechanism of HIV-1 restriction: TRIM11 suppresses reverse transcription (RING-dependent) and inhibits NF-κB-driven LTR activity (RING-independent), while HIV-1 Vpr counteracts TRIM11 by regulating its protein levels.

    Evidence Deletion mutants, quantitative PCR of reverse transcripts, LTR/NF-κB luciferase reporters, overexpression/knockdown

    PMID:25105968

    Open questions at the time
    • Mechanism of Vpr-mediated TRIM11 regulation not resolved
    • No identification of the ubiquitinated viral target
  7. 2016 High

    Uncovering a non-degradative autophagy arm: TRIM11 auto-polyubiquitinates at K458 to recruit the cargo receptor p62 and direct AIM2 for selective autophagic degradation, thereby suppressing inflammasome activation — establishing TRIM11 as an autophagy adapter.

    Evidence Co-IP, K458 site-directed mutagenesis, autophagy inhibitor experiments, and IL-1β/IL-18 maturation assays

    PMID:27498865

    Open questions at the time
    • Whether other TRIM11 substrates are also degraded by autophagy was unknown
    • Structural basis of p62 recognition of TRIM11 ubiquitin chains not determined
  8. 2016 High

    Demonstrating direct antiviral capsid targeting: TRIM11 binds HIV-1 capsid and accelerates uncoating via microtubule-dependent mechanisms, reducing reverse transcription; the capsid G89V mutation escapes this restriction.

    Evidence In vitro capsid binding, proximity ligation, fate-of-capsid assay, microtubule inhibitors, capsid mutant analysis

    PMID:27737691

    Open questions at the time
    • Whether TRIM11 ubiquitinates capsid directly was not shown
    • Relevance in primary immune cells not assessed
  9. 2018 High

    Establishing TRIM11 as a proteasome activator: TRIM11 binds the 26S proteasome and competitively displaces the inhibitory deubiquitinase USP14, enhancing global proteolytic capacity — a mechanism distinct from its E3 ligase function.

    Evidence In vitro proteasome activity assays, USP14 competition binding assays, reciprocal Co-IP, cell-based degradation assays

    PMID:29581427

    Open questions at the time
    • Structural basis of proteasome/USP14 competition not resolved
    • Relative contribution of proteasome activation versus direct substrate ubiquitination to aggregate clearance unclear
  10. 2019 Medium

    Broadening TRIM11 signal transduction roles: TRIM11 ubiquitinates and degrades Axin1 to activate Wnt/β-catenin signaling, and separately ubiquitinates PHLPP1 to sustain AKT phosphorylation, revealing TRIM11 as a positive regulator of multiple pro-survival/pro-proliferative pathways.

    Evidence Co-IP, ubiquitination assays, AKT/β-catenin inhibitor rescue experiments in lymphoma and chordoma cells

    PMID:31719797 PMID:31786079

    Open questions at the time
    • In vivo confirmation limited to xenografts
    • Substrate selectivity mechanism unknown
    • Whether these pathways are relevant in non-cancer contexts not addressed
  11. 2020 High

    Defining TRIM11 as a bona fide ATP-independent chaperone and disaggregase: purified TRIM11 prevents α-synuclein fibrillization and dissolves preformed amyloid fibrils in vitro, and AAV-delivered TRIM11 rescues Parkinson's disease pathology in mice, establishing a direct proteostasis function beyond ubiquitin ligation.

    Evidence In vitro aggregation/dissolution assays with purified protein, SUMO ligase reconstitution, AAV intracranial delivery in PD mouse model with motor behavior testing

    PMID:33264628

    Open questions at the time
    • Structural basis of chaperone/disaggregase activity undetermined
    • Whether chaperone and SUMO ligase activities are mechanistically coupled or independent unclear
    • Efficacy in human neurons not tested
  12. 2023 High

    Extending the chaperone/disaggregase paradigm to tauopathy: TRIM11 prevents tau misfolding, dissolves preformed tau fibrils, promotes tau proteasomal degradation, and ameliorates pathology and cognitive deficits across multiple tauopathy mouse models; TRIM11 is downregulated in Alzheimer's disease brains.

    Evidence In vitro chaperone/disaggregation/degradation assays, AAV delivery in multiple tauopathy mouse models, behavioral testing, neuropathology

    PMID:37499037

    Open questions at the time
    • Human genetic evidence linking TRIM11 to AD risk absent
    • Whether TRIM11 downregulation is cause or consequence of disease not established
  13. 2023 High

    Establishing an immune-regulatory circuit: TRIM11-mediated autophagic degradation of AIM2 in CD4+ T cells negatively regulates Treg differentiation by suppressing AKT/FOXO1 signaling, MYC activity, and glycolysis, linking TRIM11 to adaptive immune homeostasis.

    Evidence Co-IP, ubiquitination assay, T cell differentiation assays, AKT/FOXO1 phosphorylation, EAE mouse model

    PMID:37804507

    Open questions at the time
    • Whether TRIM11 affects other T cell subsets not addressed
    • Human T cell validation lacking
  14. 2024 Medium

    Confirming TRIM11 SUMO E3 ligase activity on a disease-relevant substrate: TRIM11 catalyzes SUMO1 modification of tau at specific lysine residues, as demonstrated by lysine-to-arginine mutagenesis.

    Evidence Co-expression SUMOylation assays with site-directed mutagenesis

    PMID:39286522

    Open questions at the time
    • Downstream consequences of tau SUMOylation for degradation versus aggregation not fully resolved
    • In vivo relevance of tau SUMOylation not tested
  15. 2025 High

    Revealing a mutual regulatory axis with JAK1: JAK1 phosphorylates TRIM11, reducing its K48-linked ubiquitination and stabilizing it, while TRIM11 reciprocally promotes K63-linked ubiquitination of JAK1 to suppress JAK/STAT signaling and IFN-γ-induced PD-L1 expression, enhancing anti-tumor immunity.

    Evidence Reciprocal Co-IP, linkage-specific ubiquitination assays, phosphorylation mapping, STAT signaling and CTL killing assays, mouse tumor models

    PMID:41203822

    Open questions at the time
    • Phosphorylation sites on TRIM11 not fully mapped
    • Whether other JAK family members similarly regulate TRIM11 unknown
    • Clinical relevance to immunotherapy response not established

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the structural basis for TRIM11's ATP-independent disaggregase activity, how substrate selectivity is determined across its diverse degradation targets, whether the chaperone and E3 ligase/SUMO ligase functions are mechanistically separable in vivo, and the physiological relevance of TRIM11 downregulation in Alzheimer's disease.
  • No high-resolution structure of TRIM11 or TRIM11-substrate complexes
  • No systematic identification of the E2 enzymes partnering with TRIM11 for different ubiquitin chain types
  • In vivo genetic loss-of-function (knockout mouse) phenotype not reported in the primary mechanistic literature

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 11 GO:0016874 ligase activity 4 GO:0044183 protein folding chaperone 2 GO:0098772 molecular function regulator activity 2
Localization
GO:0005829 cytosol 3 GO:0005634 nucleus 2
Pathway
R-HSA-162582 Signal Transduction 5 R-HSA-168256 Immune System 4 R-HSA-9612973 Autophagy 3 R-HSA-5357801 Programmed Cell Death 1
Partners
AIM2AXIN1JAK1MAPTPAX6PHLPP1TBK1USP14

Evidence

Reading pass · 28 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2003 TRIM11 binds to Humanin (HN) neuroprotective peptide via its coiled-coil and B30.2 domains, and promotes ubiquitin-mediated proteasomal degradation of intracellular HN; deletion of the RING domain or proteasome inhibition abolished this effect. Yeast two-hybrid screening, co-expression assays, deletion mutagenesis, proteasome inhibitor treatment The European journal of neuroscience Medium 12670303
2006 TRIM11 binds to ARC105 (activator-recruited cofactor 105-kDa component) and promotes its ubiquitin-proteasome-dependent degradation, thereby suppressing ARC105-mediated transcriptional activation of TGFβ signaling. Co-immunoprecipitation, co-expression ubiquitination assay, proteasome inhibitor treatment, transcriptional reporter assay FEBS letters Medium 16904669
2005 TRIM11 physically interacts with the C-terminal domain of PAX6; C-terminal PAX6 mutations found in patients with eye malformations reduced or abolished this interaction. Yeast two-hybrid library screen BMC genetics Low 16098226
2008 TRIM11 interacts with PAX6 via its B30.2 domain and promotes PAX6 degradation via the ubiquitin-proteasome system; TRIM11 overexpression decreases endogenous PAX6 protein levels and represses Pax6-dependent transactivation and neurogenesis, while abrogation of TRIM11 increases insoluble Pax6 and enhances apoptosis; the B30.2 domain is essential for clearance of insoluble proteins; Pax6 directly regulates Trim11 expression forming an autoregulatory feedback loop. Co-immunoprecipitation, overexpression/knockdown in cortical progenitors, in vivo cortex electroporation, transcriptional reporter assays, ChIP Genes & development High 18628401
2008 TRIM11 physically interacts with the homeodomain transcription factor Phox2b via its B30.2/SPRY domain, and co-expression of Trim11 with Phox2b further increases dopamine beta-hydroxylase (DBH) gene mRNA levels in primary avian neural crest stem cells. Yeast two-hybrid, protein-protein interaction assays, co-expression in primary NCSC culture, RT-PCR Biochemical and biophysical research communications Medium 18275850
2012 TRIM11 mediates proteasomal degradation of polyalanine-expanded PHOX2B (mutant causing congenital central hypoventilation syndrome), rescuing PHOX2B transcriptional activity; clearance of mutant PHOX2B by TRIM11 correlates with rescue of wild-type PHOX2B function. Co-expression assays, ubiquitination assays, proteasome inhibitor treatment, transcriptional reporter assay, neuroblastoma cell experiments Journal of molecular medicine Medium 22307522
2012 TRIM11 knockdown in glioblastoma cells inhibits proliferation, migration, and invasion, significantly decreases EGFR levels and MAPK activity, and downregulates HB-EGF mRNA; TRIM11 overexpression promotes tumorsphere formation and glial tumor growth in vivo, suggesting TRIM11 acts through the EGFR signaling pathway. siRNA knockdown, overexpression, in vitro proliferation/migration/invasion assays, in vivo xenograft, western blot Oncogene Medium 23178488
2013 TRIM11 negatively regulates IFNβ production by interacting with TBK1 (via CC domain of TRIM11 and CC2 domain of TBK1), inhibiting IRF3 phosphorylation and dimerization; this interaction was enhanced by TBK1 adaptor proteins NAP1, SINTBAD, and TANK. TRIM11 overexpression enhanced viral infectivity while knockdown had the opposite effect. Co-immunoprecipitation, deletion mutagenesis, IFNβ promoter reporter assays, IRF3 phosphorylation assay, viral infectivity assay, siRNA knockdown PloS one High 23675467
2016 TRIM11 binds to AIM2 via its PS domain and undergoes auto-polyubiquitination at K458 to promote association with the autophagic cargo receptor p62, mediating selective autophagic degradation of AIM2 and suppression of AIM2 inflammasome activation. Co-immunoprecipitation, site-directed mutagenesis (K458), ubiquitination assay, autophagy inhibitor experiments, siRNA knockdown, IL-1β/IL-18 maturation assays Cell reports High 27498865
2016 TRIM11 interacts with HIV-1 capsid and accelerates viral uncoating, reducing reverse transcription; microtubule dynamics contribute to TRIM11-mediated premature capsid disassembly; the capsid G89V mutation confers insensitivity to TRIM11 restriction. In vitro binding assay, in situ proximity ligation assay, fate-of-capsid assay, quantitative PCR, microtubule dynamics inhibitors, capsid mutant analysis Retrovirology High 27737691
2014 TRIM11 suppresses early steps of HIV-1 transduction (reducing reverse transcripts) and inhibits HIV-1 LTR activity via inhibition of NF-κB; the RING domain is required for the former but dispensable for the latter; HIV-1 Vpr regulates TRIM11 protein levels independently of VprBP-associated proteasome machinery. Deletion mutant experiments, luciferase reporter assay (LTR/NF-κB), quantitative PCR of reverse transcripts, overexpression/knockdown PloS one Medium 25105968
2018 TRIM11 binds to USP14 (a deubiquitinase and noncatalytic proteasome inhibitor) and precludes USP14-proteasome association, thereby activating the proteasome and enhancing overall proteolytic rate; TRIM11 also binds directly to the proteasome. TRIM11 is upregulated upon heat shock and is required for tumor growth. Co-immunoprecipitation, in vitro proteasome activity assays, proteasome binding assays, USP14 competition assays, cell-based degradation assays Nature communications High 29581427
2018 TRIM11 interacts with and stabilizes HSF1, increasing HSF1 nuclear levels, and cooperates with HSF1 to suppress the anti-tumor effect of proteotoxic stress drugs; TRIM11 promotes removal of protein aggregates in an HSF1-dependent manner. Co-immunoprecipitation, nuclear fractionation, protein aggregate clearance assays, drug sensitivity assays Cell cycle Medium 30563406
2019 TRIM11 interacts with Axin1 and promotes its ubiquitination and degradation, thereby activating β-catenin signaling in lymphoma cells. Co-immunoprecipitation, ubiquitination detection, western blot, β-catenin inhibitor rescue experiments Experimental cell research Medium 31786079
2019 TRIM11 promotes mono-ubiquitination of YAP (via interaction between TRIM11 RING domain and YAP WW domain), prolonging YAP protein half-life and activating Hippo-YAP/TEAD target genes in anaplastic thyroid cancer; SOX13 activates TRIM11 transcription by binding to the TRIM11 promoter. Co-immunoprecipitation, ubiquitin-based immunoprecipitation, protein half-life assay, reporter assays, promoter analysis International journal of biological sciences Medium 33613102
2020 TRIM11 promotes mono-ubiquitination of ERα (via interaction between TRIM11 RING domain and ERα N-terminus in the cytoplasm), enhancing ERα protein stability and ERα-dependent transcriptional activity and cell proliferation in breast cancer. Co-immunoprecipitation, domain deletion mutagenesis, ubiquitination assay, protein stability assay, RNA-seq, ERE reporter assay Neoplasia Medium 32599554
2020 TRIM11 promotes p62-selective autophagic degradation of Daple (a Gα-interacting protein), upregulating β-catenin expression to induce ABCC9 transcription and thereby enhancing multidrug resistance in nasopharyngeal carcinoma. Co-immunoprecipitation, ubiquitination assay, autophagy inhibition experiments, western blot, in vivo xenograft Oncogenesis Medium 32382014
2020 TRIM11 functions as an ATP-independent molecular chaperone and disaggregase, preventing formation of protein aggregates and dissolving pre-existing aggregates including amyloid fibrils; these activities cooperate with TRIM11 SUMO ligase activity to degrade aberrant proteins. TRIM11 abrogates α-synuclein fibrillization and, when delivered via AAV intracranially, mitigates α-synuclein pathology, neurodegeneration, and motor impairments in a PD mouse model. In vitro aggregation assays, amyloid fibril dissolution assays, SUMO ligase assays, cell viability assays, AAV delivery in PD mouse model, motor behavior testing Cell reports High 33264628
2021 TRIM11 interacts with and colocalizes with UBE2N, and promotes gemcitabine resistance and suppresses ferritinophagy through UBE2N-TAX1BP1 signaling in pancreatic ductal adenocarcinoma. Co-immunoprecipitation, western blot, cell viability assay, xenograft model Journal of cellular physiology Low 33629745
2019 TRIM11 interacts with PHLPP1 (a protein phosphatase that dephosphorylates AKT) and promotes PHLPP1 ubiquitination, reducing PHLPP1 protein levels and sustaining AKT phosphorylation in chordoma cells. Co-immunoprecipitation, ubiquitination assay, AKT inhibitor rescue, western blot Cancer cell international Medium 31719797
2022 TRIM11 interacts with Axin1 via Co-IP and destabilizes Axin1 protein, activating the Wnt/β-catenin pathway in gastric cancer; TRIM11 and Axin1 expression are negatively correlated in GC tissues. Co-immunoprecipitation, cycloheximide chase assay, immunofluorescence, western blot, rescue experiments with Axin1 siRNA Journal of oncology Medium 35237324
2023 TRIM11 promotes proteasomal degradation of mutant and superfluous normal tau, acts as a molecular chaperone to prevent tau misfolding, and functions as a disaggregase to dissolve preformed tau fibrils; intracranial AAV delivery of TRIM11 ameliorated pathology, neuroinflammation, and cognitive impairments in multiple animal models of tauopathies. TRIM11 is markedly downregulated in AD brains. In vitro aggregation/disaggregation assays, proteasome degradation assays, chaperone assays, AAV delivery in tauopathy mouse models, behavioral testing, neuropathology Science High 37499037
2023 TRIM11 interacts with AIM2 and promotes selective autophagic degradation of AIM2 (via AIM2 ubiquitination and p62 binding) in CD4+ T cells, specifically negatively regulating Treg cell differentiation and attenuating AKT/FOXO1 phosphorylation, MYC signaling, and glycolysis downstream of AIM2. Co-immunoprecipitation, ubiquitination assay, T cell differentiation assays, AKT/FOXO1 phosphorylation assay, EAE mouse model Cell reports High 37804507
2024 TRIM11 increases SUMO1 modification of tau (both 2N4R- and 0N4R-tau), acting as a SUMO E3 ligase; mutation of the target lysine residue to arginine abolished SUMO1 modification by TRIM11. Co-expression SUMOylation assays, lysine-to-arginine mutagenesis, western blot Biochemistry and biophysics reports Medium 39286522
2025 TRIM11 and JAK1 interact and mutually regulate each other: JAK1 phosphorylates TRIM11, reducing its K48-linked polyubiquitination and stabilizing it; TRIM11 in turn promotes K63-linked polyubiquitination of JAK1, inhibiting downstream JAK/STAT signaling and reducing IFN-γ-induced PD-L1 expression, thereby enhancing cytotoxic T lymphocyte activity. Co-immunoprecipitation, ubiquitination assays (K48/K63-linkage specific), phosphorylation assays, STAT signaling assays, CTL killing assays, mouse tumor models Cell death and differentiation High 41203822
2021 TRIM11 promotes K63-linked ubiquitination of ACSL4, leading to its degradation and suppression of ferroptosis in NSCLC; METTL3 enhances m6A modification of TRIM11 mRNA via an IGF2BP1-dependent mechanism, stabilizing TRIM11 mRNA and increasing TRIM11 expression. IP/ubiquitination assay, RNA immunoprecipitation, luciferase reporter, MeRIP assay, protein stability analysis, xenograft Naunyn-Schmiedeberg's archives of pharmacology Medium 40668412
2025 TRIM11 promotes ubiquitination of HOXB9 and regulates the NF-κB signaling pathway in sepsis-associated inflammation, reversing HOXB9-induced NF-κB activation. Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, western blot, flow cytometry Molecular biology reports Low 39903348
2023 TRIM11 ubiquitinates PHLPP1, reducing PHLPP1 protein levels and activating AKT signaling in cervical cancer; TRIM11 mRNA is stabilized by m6A modification mediated by METTL14 and read by IGF2BP1. Co-immunoprecipitation, ubiquitination assay, MeRIP assay, RNA stability assay, actinomycin D treatment Neoplasma Medium 38053376

Source papers

Stage 0 corpus · 69 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2016 TRIM11 Suppresses AIM2 Inflammasome by Degrading AIM2 via p62-Dependent Selective Autophagy. Cell reports 146 27498865
2010 The complete genome of Propionibacterium freudenreichii CIRM-BIA1, a hardy actinobacterium with food and probiotic applications. PloS one 126 20668525
2003 A tripartite motif protein TRIM11 binds and destabilizes Humanin, a neuroprotective peptide against Alzheimer's disease-relevant insults. The European journal of neuroscience 105 12670303
2008 Trim11 modulates the function of neurogenic transcription factor Pax6 through ubiquitin-proteosome system. Genes & development 96 18628401
2020 TRIM11 facilitates chemoresistance in nasopharyngeal carcinoma by activating the β-catenin/ABCC9 axis via p62-selective autophagic degradation of Daple. Oncogenesis 73 32382014
2023 TRIM11 protects against tauopathies and is down-regulated in Alzheimer's disease. Science (New York, N.Y.) 72 37499037
2016 TRIM11, a direct target of miR-24-3p, promotes cell proliferation and inhibits apoptosis in colon cancer. Oncotarget 70 27888625
2016 TRIM11 overexpression promotes proliferation, migration and invasion of lung cancer cells. Journal of experimental & clinical cancer research : CR 68 27329103
2018 Cutaneous Melanocytoma With CRTC1-TRIM11 Fusion: Report of 5 Cases Resembling Clear Cell Sarcoma. The American journal of surgical pathology 64 29240581
2012 TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth. Oncogene 62 23178488
2018 TRIM11 activates the proteasome and promotes overall protein degradation by regulating USP14. Nature communications 60 29581427
2020 TRIM11 Prevents and Reverses Protein Aggregation and Rescues a Mouse Model of Parkinson's Disease. Cell reports 52 33264628
2018 Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype. Annals of neurology 41 30066433
2013 TRIM11 negatively regulates IFNβ production and antiviral activity by targeting TBK1. PloS one 41 23675467
2022 Cutaneous Melanocytic Tumor With CRTC1::TRIM11 Translocation : An Emerging Entity Analyzed in a Series of 41 Cases. The American journal of surgical pathology 40 35993578
2020 TRIM11 promotes breast cancer cell proliferation by stabilizing estrogen receptor α. Neoplasia (New York, N.Y.) 40 32599554
2021 SOX13/TRIM11/YAP axis promotes the proliferation, migration and chemoresistance of anaplastic thyroid cancer. International journal of biological sciences 39 33613102
2016 TRIM11 Upregulation Contributes to Proliferation, Invasion, and EMT of Hepatocellular Carcinoma Cells. Oncology research 39 28244856
2017 Proliferation and invasion of ovarian cancer cells are suppressed by knockdown of TRIM11. Oncology letters 38 28781653
2016 An HIV-1 capsid binding protein TRIM11 accelerates viral uncoating. Retrovirology 36 27737691
2021 TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma. Journal of cellular physiology 34 33629745
2019 TRIM11 promotes proliferation and glycolysis of breast cancer cells via targeting AKT/GLUT1 pathway. OncoTargets and therapy 33 31388304
2017 Upregulated TRIM11 Exerts its Oncogenic Effects in Hepatocellular Carcinoma Through Inhibition of P53. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 33 29190611
2015 Activation of AKT1/GSK-3β/β-Catenin-TRIM11/Survivin Pathway by Novel GSK-3β Inhibitor Promotes Neuron Cell Survival: Study in Differentiated SH-SY5Y Cells in OGD Model. Molecular neurobiology 32 26660108
2006 TRIM11 binds to and destabilizes a key component of the activator-mediated cofactor complex (ARC105) through the ubiquitin-proteasome system. FEBS letters 32 16904669
2019 CRTC1-TRIM11 fusion defined melanocytic tumors: A series of four cases. Journal of cutaneous pathology 30 31237704
2021 TRIM11 Promotes Proliferation, Migration, Invasion and EMT of Gastric Cancer by Activating β-Catenin Signaling. OncoTargets and therapy 29 33658804
2019 The topological key lncRNA H2k2 from the ceRNA network promotes mesangial cell proliferation in diabetic nephropathy via the miR-449a/b/Trim11/Mek signaling pathway. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 29 31336052
2019 TRIM11 promotes tumor angiogenesis via activation of STAT3/VEGFA signaling in lung adenocarcinoma. American journal of cancer research 28 31598402
2019 TRIM11 promotes lymphomas by activating the β-catenin signaling and Axin1 ubiquitination degradation. Experimental cell research 28 31786079
2019 Expression of Tripartite Motif-Containing Proteactiin 11 (TRIM11) is Associated with the Progression of Human Prostate Cancer and is Downregulated by MicroRNA-5193. Medical science monitor : international medical journal of experimental and clinical research 26 30608062
2021 Dermal melanocytic tumor with CRTC1-TRIM11 fusion: Report of two additional cases with review of the literature of an emerging entity. Journal of cutaneous pathology 21 33586183
2012 A temporal-omic study of Propionibacterium freudenreichii CIRM-BIA1 adaptation strategies in conditions mimicking cheese ripening in the cold. PloS one 21 22253706
2022 Cutaneous melanocytic tumor with CRTC1::TRIM11 fusion and prominent epidermal involvement: A case report. Journal of cutaneous pathology 19 35751643
2019 A case report of cutaneous melanocytoma with CRTC1-TRIM11 fusion: Is CMCT distinct from clear cell sarcoma of soft tissue? Pathology international 19 31276279
2008 Trim11 increases expression of dopamine beta-hydroxylase gene by interacting with Phox2b. Biochemical and biophysical research communications 18 18275850
2005 A screen for proteins that interact with PAX6: C-terminal mutations disrupt interaction with HOMER3, DNCL1 and TRIM11. BMC genetics 18 16098226
2020 TRIM11 stimulates the proliferation of gastric cancer through targeting CPEB3/EGFR axis. Journal of B.U.ON. : official journal of the Balkan Union of Oncology 17 33099959
2023 TRIM11 attenuates Treg cell differentiation by p62-selective autophagic degradation of AIM2. Cell reports 16 37804507
2012 The E3 ubiquitin ligase TRIM11 mediates the degradation of congenital central hypoventilation syndrome-associated polyalanine-expanded PHOX2B. Journal of molecular medicine (Berlin, Germany) 16 22307522
2022 The E3 Ubiquitin Ligase TRIM11 Facilitates Gastric Cancer Progression by Activating the Wnt/β-Catenin Pathway via Destabilizing Axin1 Protein. Journal of oncology 15 35237324
2020 miR-5193, regulated by FUT1, suppresses proliferation and migration of ovarian cancer cells by targeting TRIM11. Pathology, research and practice 15 32823233
2018 TRIM11 cooperates with HSF1 to suppress the anti-tumor effect of proteotoxic stress drugs. Cell cycle (Georgetown, Tex.) 14 30563406
2019 Silencing of TRIM11 suppresses the tumorigenicity of chordoma cells through improving the activity of PHLPP1/AKT. Cancer cell international 12 31719797
2023 TRIM11 regulated by m6A modification promotes the progression of cervical cancer by PHLPP1 ubiquitination. Neoplasma 11 38053376
2021 Tripartite motif protein 11 (TRIM11), an oncogene for human lung cancer via the DUSP6-mediated ERK1/2 signaling pathway. Cancer biology & therapy 10 33970779
2014 The human antiviral factor TRIM11 is under the regulation of HIV-1 Vpr. PloS one 10 25105968
2024 Ulcerated CRTC1::TRIM11 cutaneous tumor with metastases. Journal of cutaneous pathology 9 38877838
2021 Knockdown of TRIM11 suppresses cell progression and apoptosis of cervical cancer cells via PI3K/AKT pathway. American journal of translational research 9 34650700
2025 Malignant CRTC1::TRIM11 Cutaneous Tumor With Lethal Outcome: Histopathologic and Molecular Findings. Journal of cutaneous pathology 8 40452552
2024 Cutaneous melanocytic tumor with CRTC1::TRIM11 fusion: a case report. Diagnostic pathology 8 38184586
2023 TRIM11 Posttranscriptionally Modulated by miR-5193 Facilitates Tumor Growth and Metastasis of Prostate Cancer. Technology in cancer research & treatment 8 37248611
2023 TRIM11 promotes cell proliferation of non-small cell lung cancer through the inhibition of ferroptosis by AMPK. The clinical respiratory journal 8 37604203
2024 SUMO1 modification of 0N4R-tau is regulated by PIASx, SENP1, SENP2, and TRIM11. Biochemistry and biophysics reports 6 39286522
2021 Cutaneous Melanocytic Tumor with CRTC1::TRIM11 Fusion: Review of the Literature of a Potentially Novel Entity. Biology 6 34943200
2020 The BAHD Acyltransferase BIA1 Uses Acetyl-CoA for Catabolic Inactivation of Brassinosteroids. Plant physiology 5 32611786
2021 Knockdown of TRIM5α or TRIM11 increases lentiviral vector transduction efficiency of human Muller cells. Experimental eye research 4 33440192
2021 LncRNA LUADT1 is Upregulated in Mantle Cell Lymphoma and Modulates TRIM11 by Sponging miR-24-3p to Inhibit Cell Apoptosis. Critical reviews in eukaryotic gene expression 4 34591388
2025 A Case of a CRTC1::TRIM11 Cutaneous Tumor With Venous and Lymphatic Invasion and Lymph Node Metastasis. Cureus 3 40491616
2022 TRIM11, a new target of p53, facilitates the migration and invasion of nasopharyngeal carcinoma cells. Molecular biology reports 3 36376537
2025 The METTL3/IGF2BP1 axis-mediated m6 A modification of TRIM11 mRNA suppresses ferroptosis and accelerates malignant progression in non-small cell lung cancer cells by degrading ACSL4. Naunyn-Schmiedeberg's archives of pharmacology 1 40668412
2026 CRTC1::TRIM11 Cutaneous Tumors With Atypia: Melanoma Mimicry, Aggressive Potential, and Methylation Classifier Limitations. Genes, chromosomes & cancer 0 42015602
2025 TRIM11 modulates sepsis progression by promoting HOXB9 ubiquitination and inducing the NF-κB signaling pathway. Molecular biology reports 0 39903348
2025 CRTC1::TRIM11 Cutaneous Tumor Mimicking Primary Dermal Melanoma: Case Report With Literature Review. The American Journal of dermatopathology 0 40857736
2025 TRIM11 potentiates antitumor immunity via inhibition of the IFN-γ/PD-L1 axis. Cell death and differentiation 0 41203822
2025 [Clinicopathological characteristics of cutaneous melanocytic tumor with CRTC1::TRIM11 fusion of three cases]. Zhonghua bing li xue za zhi = Chinese journal of pathology 0 41355105
2025 Cutaneous Melanocytic Tumor With CRTC1::TRIM11 Fusion: A Case Report. Cureus 0 41536371
2025 Identifying TRIM11 Upregulators as Therapeutic Targets in Alzheimer's Disease: A Bayesian Network Approach. AMIA ... Annual Symposium proceedings. AMIA Symposium 0 41726401
2024 TRIM11 Prevents Ferroptosis in model of asthma by UBE2N-TAX1BP1 signaling. BMC pulmonary medicine 0 39472837